Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/16/2017 03/17/2017 03/20/2017 03/21/2017 03/22/2017 Date
2.34(c) 3.09(c) 2.78(c) 3.88(c) 3.9(c) Last
1 937 851 20 901 492 2 220 175 22 843 967 13 789 850 Volume
-7.14% +32.05% -10.03% +39.57% +0.52% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
03/22 PULMATRIX INC : Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi ..
03/22 MIDWEEK BIOTECH MOVERS : Pain Therapeutics, Inc. (NASDAQ:PTIE) and Pulmatrix, In..
03/21 PULMATRIX : Receives European Patent for its Inhaled Drug Delivery Technology
03/17 PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Entry into a Material Definitive Ag..
03/17 PULMATRIX, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
03/10 PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Results of Operations and Financial..
03/10 PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Regulation FD Disclosure
03/10 PULMATRIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
03/10 PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
03/10 PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
More news
Sector news : Bio Therapeutic Drugs
01:26p Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/22 ? Here?s Why The Pulmatrix Inc (NASDAQ:PULM) Patent Is So Important via ?  
03/22$ILUS bids building, now that .03 is solid support, we could see an uptrend. .. 
03/2218 Stocks Moving In Wednesday's PreMarket
1
03/22
3
03/21$PULM stuck out like a sore thumb today gaining 39% amidst a very red day. On.. 
More tweets
Qtime:8
News from SeekingAlpha
03/22 PREMARKET GAINERS AS OF 9 : 05 am
03/21 After Hours Gainers / Losers
03/21 Midday Gainers / Losers
03/21 HEALTHCARE - TOP GAINERS / LOSERS AS : 00 am
03/21 Pulmatrix nabs European patent for inhaled drug delivery; shares ahead 32%
Advertisement
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Full-screen chart
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
Terrance G. McGuire Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC561.02%70
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
More Results